2026-04-14T06:06:31Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/2165552025-12-05T12:42:04Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT author Donadeu, Laura author Gomez Olles, Susana author Casanova, Franc author Torija, Alba author Lopez Meseguer, Manuel author Boada Pérez, Meritxell author Kervella, Delphine author Crespo, Elena author Carrera Muñoz, Claudia author Campos Varela, Isabel author Castells, Lluís author Cortese, Maria F. author Esperalba, Juliana author Fernández Naval, Candela author Quintero, Jesús author Muñoz, Marina author Agüero, Fernando author González-Costello, José author Lladó, Laura author Favà, Alexandre author Cañas, Laura author Hoz Caballero, María Del Mar De La author Meneghini, Maria author Torres, Irina B. author Juvé, Mariona author Hafkamp, Fmj author Vila, Marta author Robles, Alba G. author Buzón, Maria José author Toapanta, Nestor author Zúñiga, José Miguel author Monforte, Víctor author Saez Giménez, Berta author Len, Oscar author Los-Arcos, Ibai author Miret, Enric author Ariceta, Gema author Pardo, Emma author Martínez, Xavier author Moreso, Francesc author Bestard Matamoros, Oriol 2024-11-18T12:13:18Z2024-11-18T12:13:18Z2024-10-082024-11-18T11:36:07Z Introduction Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear.Methods We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination.Results We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion.Discussion Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients. cc-by (c) Donadeu, Laura et al., 2024 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess SARS-CoV-2 Vacunació Trasplantament d'òrgans SARS-CoV-2 Vaccination Transplantation of organs Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion